Eli Lilly
-
India Panel Backs Eli Lilly's Mounjaro, Weight Loss Drug Set to Enter Indian Market
-
Anat Ashkenazi is Alphabet's New CFO, Replacing Ruth Porat
-
Diabetes Relief: Major Manufacturers Cap Insulin Prices at $35, Answering Calls for Affordability in the US
-
Eli Lilly's Weight-Loss Drug Users Regain Over 20 Pounds After Discontinuation, Study Reveals
-
FDA-Approved Drug Clears Psoriasis In Long-Term Clinical Trials
-
Cholesterol Drug Evacetrapib Does Not Reduce Cardiovascular Events
-
Eli Lilly's Jardiance Diabetes Treatment Steals Market Share From Rival Drugs
-
FDA Approves Eli Lilly's Drug Basaglar For Diabetes Treatment
-
Eli Lilly, Incyte Announce Baricitinib Superior To Methotrexate In Alleviating Rheumatoid Arthritis
-
Eli Lilly In Legal Hot Water For Cymbalta WIthdrawal Risks
-
Court Sides With Eli Lilly In Alimta Drug Patent Suit
Most Popular
